MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

BerGenBio Partners with Tempus to Advance Development in STK11-Mutant Non-Small Cell Lung Cancer

NextEdge Admin

20 Aug 2024

2 min 10 sec

BerGenBio ASA , a clinical-stage biopharmaceutical company, has announced a collaboration with Tempus, a leader in AI-driven precision medicine, to advance the development of BerGenBio's selective AXL inhibitor, bemcentinib, for first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients with STK11 mutations (STK11m). This partnership is focused on BerGenBio's ongoing BGBC016 Phase 1b/2a trial, which evaluates the benefit of adding bemcentinib to the current standard of care (immunotherapy + doublet chemotherapy) in STK11m patients, a group with poor outcomes and no targeted therapies available.

Through this collaboration, BerGenBio will gain access to a tailored cohort of Tempus' real-world clinical and molecular data, creating a synthetic control that provides a contextual benchmark for the study. Tempus' AI-enabled platform will deliver customized analyses, offering deeper insights into the genomic landscape and therapeutic responses of NSCLC patients with STK11m.

Following the BGBC016 study, the data insights will be presented to regulatory agencies as a step toward further development of bemcentinib. Martin Olin, CEO of BerGenBio, expressed excitement about the collaboration, emphasizing its potential to improve outcomes for NSCLC patients with STK11 mutations by enhancing the understanding of disease biology and treatment responses.

Kate Sasser, Chief Scientific Officer at Tempus, highlighted the partnership's goal to accelerate the development of precision therapies for this challenging patient population, aiming to redefine the standard of care.